News Sentiment

NKTR sentiment intelligence

Nektar Therapeutics news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 70.36 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-1.0% over one week, +18.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -1.0% Price digesting
Trend fit Trend active 18.5% over four weeks
Fair value 150.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 43
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 8
Stock Titan 5
PR Newswire 5
ACCESS Newswire 4
simplywall.st 4
Stocktwits 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 16
Regulatory and legal 4
Analyst action 3
Guidance 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 67
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. B

Tone
Negative 28/100
Event
Regulatory and legal
Published
10 Jul 2026 07:09
Source
ACCESS Newswire
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR)

Two healthcare companies, Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR), received bullish sentiments from analysts. H.C. Wainwright reiterated a Buy rating for Pyxis Oncology with a $7.00 price target, and for Nektar Therapeutics with a $185.00 price target, both implying

Tone
Positive 74/100
Event
Analyst action
Published
07 Jul 2026 18:39
Source
The Globe and Mail
TradingView Direct company coverage

Enterprise value to EBITDA forward of Nektar Therapeutics – LSE:0UNL

This article provides access to the enterprise value to EBITDA forward metric for Nektar Therapeutics (LSE:0UNL) on the TradingView platform. It highlights the availability of this financial data for the company listed on the London Stock Exchange, within the Health Technology se

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 18:11
Source
TradingView
Simply Wall Street Direct company coverage

Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?

Nektar Therapeutics (NKTR) is gaining attention due to positive mid-stage data for its autoimmune pipeline, specifically in alopecia areata and upcoming late-stage trials in atopic dermatitis. Despite recent share price momentum, the stock's valuation, including a P/S ratio well

Tone
Positive 63/100
Event
Market update
Published
06 Jul 2026 06:09
Source
Simply Wall Street
Stocktwits Direct company coverage

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Shares of Nektar Therapeutics (NKTR) surged 10% as investors anticipate upcoming clinical data for its lead drug, rezpegaldesleukin, aimed at autoimmune and inflammatory diseases. The company plans to initiate late-stage trials for atopic dermatitis by the end of July 2026 and ex

Tone
Positive 76/100
Event
Market update
Published
04 Jul 2026 17:10
Source
Stocktwits
Stock Titan Direct company coverage

Nektar Therapeutics (NKTR) R&D chief sells 5,681 shares under 10b5-1 plan

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), sold 5,681 shares of common stock at $70.00 per share, totaling $397,670, on June 30, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March 13, 2026. Following the sale, Zalev

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 18:39
Source
Stock Titan
Ad-hoc-news.de Direct company coverage

Nektar Therapeutics updates its biotech strategy. Investors weigh the outlook for NKTR stock

Nektar Therapeutics is refining its biotech strategy, focusing its clinical pipeline on immunology and oncology programs amid a challenging funding environment. The company is streamlining programs, prioritizing indications with clear development pathways, and emphasizing operati

Tone
Neutral 50/100
Event
Guidance
Published
03 Jul 2026 13:39
Source
Ad-hoc-news.de
Investing.com Canada Direct company coverage

Form 4 Nektar Therapeutics For: 2 July By Investing.com

This article reports a Form 4 filing for Nektar Therapeutics (NKTR) on July 2. Form 4s disclose changes in beneficial ownership of securities by company insiders. The article includes the stock symbol NKTR and its performance data.

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 04:39
Source
Investing.com Canada
Investing.com Direct company coverage

Nektar Therapeutics R&D chief sells $397,670 of common stock

Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, sold 5,681 shares of common stock for $397,670 on June 30, 2026, as per a Rule 10b5-1 trading plan. The stock has seen significant gains, but InvestingPro analysis suggests it might be overvalued. Nektar Therapeutics al

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:10
Source
Investing.com
Timothy Sykes Direct company coverage

Nektar Therapeutics Stock Climbs As Immunology Sentiment Improves

Nektar Therapeutics (NKTR) stock surged due to positive trial data and optimism surrounding partnerships, particularly after Canaccord cited the company as a beneficiary of AbbVie's acquisition of Apogee Therapeutics. The company is actively hiring and aligning talent with its fo

Tone
Positive 72/100
Event
Deals and strategy
Published
02 Jul 2026 21:10
Source
Timothy Sykes
Simply Wall Street Direct company coverage

How Nektar Therapeutics’ Broad FTSE Russell Index Inclusion Will Impact Nektar Therapeutics (NKTR) Investors

Nektar Therapeutics (NKTR) has been included in several FTSE Russell indices, including the Russell 2000, 2500, and 3000, which is expected to increase its visibility and trading liquidity. While this broad index inclusion doesn't change the company's fundamental challenges, it m

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jul 2026 11:10
Source
Simply Wall Street
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them to participate in the investi

Tone
Negative 19/100
Event
Regulatory and legal
Published
02 Jul 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to contact them for more in

Tone
Negative 30/100
Event
Regulatory and legal
Published
01 Jul 2026 16:10
Source
ACCESS Newswire
Stock Titan Direct company coverage

Jonathan Zalevsky (NKTR) sells 5,737 shares via 10b5-1 plan

Jonathan Zalevsky, an individual associated with NEKTAR THERAPEUTICS (NKTR), has reported the sale of 5,737 shares of common stock through a pre-arranged 10b5-1 plan. The sales occurred in two transactions: 199 shares on May 19, 2026, for $13,036.49, and 5,538 shares on June 15,

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 03:38
Source
Stock Titan
marketscreener.com Direct company coverage

Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Value Benchmark

Nektar Therapeutics (NasdaqCM: NKTR), a clinical-stage biotechnology company, has been added to the Russell 2000 Value Benchmark. The company focuses on developing treatments for autoimmune, chronic inflammatory diseases, and oncology, with its lead product candidate rezpegaldesl

Tone
Positive 64/100
Event
Market update
Published
29 Jun 2026 11:41
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 2000 Growth Benchmark

Nektar Therapeutics (NasdaqCM: NKTR) has been added to the Russell 2000 Growth Benchmark. The company is a clinical-stage biotechnology firm focused on developing treatments for autoimmune, chronic inflammatory diseases, and cancer, with lead product candidate rezpegaldesleukin u

Tone
Positive 64/100
Event
Market update
Published
29 Jun 2026 07:41
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Nektar Therapeutics(NasdaqCM: NKTR) added to Russell 3000E Growth Benchmark

Nektar Therapeutics (NasdaqCM: NKTR), a clinical-stage biotechnology company, has been added to the Russell 3000E Growth Benchmark. The company focuses on developing treatments for autoimmune, chronic inflammatory diseases, and oncology, with lead product candidate rezpegaldesleu

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 03:09
Source
www.marketscreener.com
TradingView Direct company coverage

Nektar Therapeutics Actuals & Estimates (NASDAQ:NKTR)

This article provides an overview of Nektar Therapeutics (NASDAQ:NKTR) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts, financial actuals, upcoming earnings dates, and past earnings and revenue figures. The conte

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 11:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Nektar Therapeutics – SWB:ITH0

This article from TradingView provides financial information for Nektar Therapeutics (SWB:ITH0), specifically focusing on its "Price to sales forward" metric. The content appears to be a stub or a section of a larger financial data page, showing the financial metric, period, valu

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Nektar Therapeutics – DUS:ITH0

This article provides an overview of Nektar Therapeutics (DUS:ITH0) on the Dusseldorf Stock Exchange, focusing on its financials, specifically the "Price to sales forward" metric. The content highlights that the market is currently closed with no trades. It also details the vario

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Nektar Therapeutics – NASDAQ:NKTR

This article provides financial information for Nektar Therapeutics (NASDAQ: NKTR), specifically focusing on its forward price-to-earnings ratio. It is a data-oriented page from TradingView, presenting a quantitative financial metric without editorial commentary. The content feat

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Nektar Therapeutics – DUS:ITH0

This article provides financial information for Nektar Therapeutics (DUS:ITH0), specifically focusing on its Enterprise Value to EBITDA forward metric. It displays a table showing the period, value, change, and percentage change for this financial indicator. The page appears to b

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

NKTR Forecast — Price Target — Prediction for 2027

This article provides a forecast for Nektar Therapeutics (NKTR) stock, including analyst price targets, historical performance, and key financial metrics. Analysts have a maximum price target of $192.00 and a minimum of $80.00 for NKTR. The company's stock has seen significant gr

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 13:09
Source
TradingView